• Trinity Biotech entered a fifth credit agreement amendment dated November 6, 2026, with lenders led by administrative agent Perceptive Credit Holdings III.
• The amendment conditionally waives minimum liquidity covenant compliance for June through October 2026, including resulting defaults.
• Borrowers reported liquidity covenant breaches for June, July and August.
• Previous terms required unrestricted cash of $1 million through September 30, increasing to $3 million October 1.
• An outstanding Amended and Restated Note with original principal of $96.16 million will become the Second A&R Note upon effectiveness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-002349), on November 12, 2026, and is solely responsible for the information contained therein.